FLT3 and leukemia: However, in combination with sorafenib (SOME), it induced remission (CR/CRi) in 72% of patients with R/R FLT3-ITD AML, with a deeper molecular response and extended response duration (median overall survival and leukaemia-free survival being 43.6 and 22.4 weeks respectively) among responders [20].